Clearmind shares CMND-100 trial insights

• Clearmind Medicine shared early investigator observations from its Phase I/IIa trial of CMND-100 for alcohol use disorder.
• Researchers reported a generally positive early safety profile with no meaningful cardiac safety concerns observed so far.
• Clearmind said the trial is evaluating MEAI’s potential as a non-hallucinogenic treatment approach for AUD.

Clearmind Medicine (NASDAQ:CMND) shared early insights from its ongoing Phase I/IIa trial of CMND-100, an investigational MEAI-based compound being evaluated for alcohol use disorder, following a June 10 webinar with study investigators from Yale and Johns Hopkins.

The update follows the company’s first-in-human study as researchers evaluate the safety, tolerability and potential treatment effects of CMND-100 compared with approaches involving traditional psychedelic compounds.

Researchers said the study has shown recruitment progress despite strict eligibility criteria and that CMND-100 may offer a treatment model without hospitalization, intensive monitoring or mandatory psychological supervision, although further research is required.

Clearmind reported that the trial has shown a promising early safety profile, with no meaningful adverse effects or cardiac safety concerns observed to date.

CMND-100 is based on MEAI, a compound being studied for potential use in alcohol use disorder and other conditions requiring further clinical evaluation.

Clearmind continues advancing the Phase I/IIa study, with investigators evaluating dose escalation, pharmacokinetics, participant experiences and potential future applications of MEAI.